Lake Street Capital Has Lowered Expectations for LifeMD (NASDAQ:LFMD) Stock Price

LifeMD (NASDAQ:LFMD) had its price target decreased by equities researchers at Lake Street Capital from $5.00 to $3.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital‘s price objective points to a potential upside of 36.67% from the stock’s current price.

A number of other analysts also recently issued reports on the stock. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. B. Riley Financial started coverage on LifeMD in a research report on Friday, September 11th. They set a “buy” rating and a $8.00 price target on the stock. BTIG Research lowered their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, KeyCorp set a $5.00 price target on LifeMD and gave the stock an “overweight” rating in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.14.

LifeMD Stock Performance

LifeMD stock traded up $0.54 during mid-day trading on Friday, hitting $2.19. 6,142,984 shares of the company traded hands, compared to its average volume of 944,039. LifeMD has a one year low of $1.60 and a one year high of $5.38. The stock has a market cap of $105.80 million, a price-to-earnings ratio of -36.58 and a beta of 2.19. The stock has a fifty day moving average price of $2.60 and a 200-day moving average price of $3.57.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $44.63 million during the quarter, compared to analysts’ expectations of $48.84 million. LifeMD had a negative net margin of 0.25% and a negative return on equity of 139.69%. Sell-side analysts predict that LifeMD will post -0.48 EPS for the current year.

Hedge Funds Weigh In On LifeMD

Large investors have recently added to or reduced their stakes in the business. Walleye Capital LLC purchased a new position in LifeMD in the 2nd quarter worth $1,338,000. Russell Investments Group Ltd. boosted its position in LifeMD by 5,801.2% during the second quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock valued at $1,300,000 after buying an additional 309,436 shares during the period. Penn Capital Management Company LLC purchased a new stake in LifeMD during the second quarter valued at about $926,000. Bank of America Corp DE purchased a new stake in LifeMD during the second quarter valued at about $1,078,000. Finally, BlackRock Inc. grew its stake in shares of LifeMD by 8.0% during the second quarter. BlackRock Inc. now owns 3,034,535 shares of the company’s stock valued at $12,533,000 after buying an additional 225,510 shares during the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD News Summary

Here’s some of the latest news about LFMD:

• Positive Sentiment: LifeMD reported a third-quarter loss of $0.11 per share, narrower than the expected $0.14 loss. Adjusted EBITDA also improved by about $3.1 million sequentially, to a loss of roughly $0.4 million, as the company reduced marketing and other non-clinical expenses. LifeMD Q3 2026 results
• Neutral Sentiment: Lake Street Capital lowered its price target from $5 to $3 but kept a Buy rating; Mizuho cut its target from $7 to $6 and maintained an Outperform rating. The retained positive ratings offer support, though both target reductions reflect more cautious expectations. Analyst rating and price target update
• Negative Sentiment: Revenue was $44.6 million, below analysts’ $48.8 million estimate. LifeMD also forecast fourth-quarter revenue of $46–$49 million, versus consensus of $61.4 million, and full-year 2026 revenue of $188–$191 million, versus $207.6 million expected. The shortfall in guidance may weigh on investor expectations for near-term growth. LifeMD Q3 2026 results and guidance

About LifeMD

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.